Longeveron Inc. (NASDAQ:LGVN)
| Market Cap | $5.37M-73.4% |
| Revenue (ttm) | $1.17M-18.9% |
| Net Income | -$22.39M-4.9% |
| EPS | -$8.11+39.0% |
| Shares Out | 3.23M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 27,258 |
| Open | $1.83 |
| Previous Close | $1.82 |
| Day's Range | $1.64 - $1.83 |
| 52-Week Range | $1.31 - $12.30 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | $10.00(+502.41%) |
| Earnings Date | Mar 16, 2027 |
About LGVN
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Next catalysts
- Mar 16, 2027Earnings report
$LGVN stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in LGVN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LGVN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LGVN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LGVN Revenue by Segment
| R&D costs | $3.96M | 39.12% |
| G&A costs | $3.31M | 32.71% |
| Personnel costs | $2.85M | 28.17% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LGVN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LGVN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LGVN
| VXFVanguard Extended Market ETF | $61.22K |
| VTIVanguard Morningstar Total Stock Market ETF | $47.55K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from LGVN’s recent data — informational, not investment advice
